Details:
Through collaboration, DreamCIS will be supporting the clinical development with Curi Bio's cutting-edge neuromuscular junction model for advancing Genetox’s Botaone (clostridium botulinum toxin Type A) for Glabellar wrinkles and lateral canthal wrinkles.
Lead Product(s): Clostridium Botulinum Toxin Type A
Therapeutic Area: Dermatology Product Name: Botaone
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Curi Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2024
Details:
LETYBO is indicated for temporary improvement in the appearance of moderate to severe glabellar frown lines in adults. It is currently available in 28 countries worldwide, with recent approvals in Europe and Canada.
Lead Product(s): LetibotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Hugel plans to effectively deliver the efficacy and safety of Letybo (letibotulinumtoxinA) by providing training for local medical staff and conducting academic programs in cooperation with major chain clinics and key opinion leaders.
Lead Product(s): LetibotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
Long-term real-world data on the effectiveness and safety of SB5 (adalimumab) biosimilars in psoriasis is limited, and study results from BADBIR demonstrate that SB5 is just as safe and effective as its reference adalimumab.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: SB5
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.
Lead Product(s): LetibotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
The launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler, into the Canadian market will enhance the available line of saypha® dermal fillers, giving aesthetic medical professionals more creative power to design a truly bespoke experience for their patients.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Saypha
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Upon the acquisition of Biogen’s equity stake, companies will continue their agreement, including commercialization of products BENEPALI (etanercept), a biosimilar of ENBREL, IMRALDITM (adalimumab), a biosimilar of Humira and FLIXABI (infliximab), a biosimilar of Remicade.
Lead Product(s): Etanercept
Therapeutic Area: Dermatology Product Name: Benepali
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Samsung Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 20, 2022